But let's go to the lights. Perhaps the brightest point, the one that has compensated for the regulatory inaction, has been the approval within the Pharmacy Commission of the Interterritorial Council of the National Health System of the action plan for generics and biosimilars. Since 2017, BioSim had been demanding a plan that, led by Health, would reach the consensus of the seventeen autonomies and this objective has been met. The preparation of this plan and the achievement of this consensus are in themselves good news; it is positive that measures such as the acceleration of the inclusion of these drugs in the pharmaceutical provision or training and information actions for professionals and citizens are included. It is true that the plan presents some points that are unacceptable, because they hurt the investments and the development of these drugs and therefore jeopardize their future. We are referring to short-term savings measures and approximations that do not have any scientific or clinical support, such as the formation of reference sets at the ATC4 level.
For BioSim, in addition, the plan should address two aspects that constitute two key momentum vectors related to prescription and acquisition. On the one hand, the incentive to doctors for the fulfillment of objectives of rational use of biosimilars in your clinical practice, as is the case in other countries. This incentive must translate into individual remuneration or budgetary improvements for the centers or services in which they are integrated. On the other, the promotion of the framework agreement as a preferred acquisition formula whose advantages, under certain conditions, are obvious.
There has also been important scientific and clinical advances in terms of a significant increase in the acceptance of biosimilars by doctors, individually and collectively, scientific societies, professional associations, etc. And improvements in information and training for health professionals and patients. In the month of February, with the support of the COF Council, the Guide to Biosimilar Medicines for Pharmacists, and in October, another for patients, developed jointly between BioSim, the General Alliance of Patients (AGP) and Spanish Patient Forum (FEP).
And facing 2020 with the hope that it will be a year full of achievements for biosimilars.
